SAN Sanofi

Sanofi names new leaders to Executive Committee

Sanofi names new leaders to Executive Committee

Sanofi names new leaders to Executive Committee

  • Natalie Bickford appointed Chief People Officer
  • Arnaud Robert appointed Chief Digital Officer
  • Julie Van Ongevalle appointed Head of Consumer Healthcare
  • Thomas Triomphe appointed Head of Sanofi Pasteur



PARIS – May 29, 2020 - Sanofi has named four new leaders to its Executive Committee. These appointments now complete the announced changes in February to further simplify the Company’s executive leadership team.

The complete Sanofi Executive Committee now includes the four heads of the Company’s global business units (Sanofi Genzyme, Sanofi Pasteur, General Medicines, and Consumer Healthcare) as well as the global Heads of Research and Development, Industrial Affairs, Finance, Human Resources, Legal and Digital.

“My objective has been to find the right blend of talented people that can make the whole team stronger than its individual parts. Sanofi needs people who can bring us new insights from the outside of the industry as well as people with world-class pharma expertise. We need leaders who come to Sanofi with a fresh perspective as well as leaders who have grown up within the company,” says Paul Hudson, Chief Executive Officer at Sanofi. “I am confident in this team’s capacity to inspire our people, execute our strategy and change the practice of medicine for patients.”

Natalie Bickford, Executive Vice President, Chief People Officer

Natalie Bickford starts on August 1, and joins Sanofi from Merlin Entertainments, the world’s second largest location-based entertainment business (which includes Legoland Resorts, Madame Tussaud’s, SEALIFE aquariums, among other brands). At Merlin, she was responsible for 30,000 employees across Europe, North America, and Asia Pacific. Ms. Bickford brings a wealth of consumer-facing experience. She held previous Human Resources leadership positions at Sodexo, AstraZeneca, and Kingfisher, has consistently demonstrated passion for engaging teams and driving change in behaviors and culture. She also has a solid track record of transforming organizations, with a strong focus on inclusion and diversity.

Arnaud Robert, Executive Vice President, Chief Digital Officer (CDO)

Arnaud Robert is currently Chief Digital Officer at Viking Cruises, a cruise line provider. He joins as Sanofi’s CDO on June 15, and will drive Sanofi’s digital, data and technology strategy. As newcomer to the pharma sector, Robert brings a strong background in consumer, omni-channel experience, platform/technology, big data and front-end digital experience. He has held previous leadership positions at The Walt Disney Company and Nike, where he designed and launched the Apple Watch l Nike+ digital community.

Julie Van Ongevalle, Executive Vice President, Head of Consumer Healthcare

Julie Van Ongevalle starts on September 1, replacing Alan Main. She is currently Global Brand President of Origins, a division of the Estée Lauder Companies, based in New York City. With more than 20 years of international experience, Van Ongevalle has built brands, from identifying accelerated growth opportunities, to building and implementing execution plans resulting in sustainable, long-term profitable growth. Her deep knowledge of consumers and digital will be essential as Sanofi advances builds a standalone, agile and multi-local brands Consumer Healthcare business.

Thomas Triomphe, Executive Vice President, Head of Sanofi Pasteur

Thomas Triomphe currently serves as Head of Franchises and Product Strategy for Sanofi Pasteur, and will be promoted to Executive Vice President, Head of Sanofi Pasteur, effective June 15.  Triomphe replaces David Loew. Triomphe joined Sanofi Pasteur in 2004 as part of a talent management program and has since held different roles of increasing responsibility in sales and marketing, at the country, regional, and global levels.

The Company extends sincere thanks to David Loew and Alan Main for their leadership and outstanding contributions. Most recently, both executives have played a critical role in harnessing Sanofi’s efforts and resources in the fight against COVID-19.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Sanofi Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Quentin Vivant

Tél.: +33 (0)1 53 77 46 46





 
 



Sanofi Investor Relations

Felix Lauscher

Tel.: +33 (0)1 53 77 45 45







Attachment

EN
29/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the ...

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025Cette nouvelle désignation de médicament orphelin souligne l’engagement de Sanofi en faveur du développement de nouveaux médicaments contre les maladies rares à médiation immunitaire Paris, le 14 août 2025. ...

 PRESS RELEASE

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neurosci...

Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de  (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un nouvel agoniste oral de TREM2, qui sera évalué dans une étude clinique de phase 2 chez des patients atteints de la maladie d’Alzheimer. En outre, l’acquisition du pipeline préclinique de Vigil renforcera la recherche de Sanofi dans diverses maladies neurodégénératives. En juin 2024, Sanofi a réalisé u...

 PRESS RELEASE

Press Release: Sanofi completes the acquisition of Vigil Neuroscience,...

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of  (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi ...

 PRESS RELEASE

Press release: Online availability of Sanofi’s half-year financial rep...

Press release: Online availability of Sanofi’s half-year financial report for 2025 Online availability of Sanofi’s half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: and downloaded from the “Investors” page, under the heading “Regulated Inform...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch